metabolic health

What does the evidence say about Inositol Cardiometabolic Randomized Trial?

Updated October 2026

Quick Answer

Inositol Cardiometabolic Randomized Trial has evidence relevant to benefits, uncertainty, and practical interpretation, but conclusions should stay close to the cited sources. One representative finding is: Background Inositol and its derivatives may help mitigate risks associated with cardiovascular diseases; however, existing evidence remains inconsistent.

Key Takeaways

  • 01Background Inositol and its derivatives may help mitigate risks associated with cardiovascular diseases; however, existing evidence remains inconsistent. [Delavar MA (2025)]
  • 02Heterogeneity was assessed via the Cochrane Chi-squared test and Galbraith plots, while the ROBI tool evaluated bias risk. [Delavar MA (2025)]
  • 03Significant reductions in BMI (WMD (95%CIs):-0.57 kg/m²(-1.10, -0.03), I²=88.6), waist-to-hip ratio(WMD (95%CI):-0.02(-0.04, -0.001), I²=84.1), and waist circumference (WMD (95%CI):-2.36 cm(-4.39, -0.33) I²=55.0) were noted with high heterogeneity and low to very low certainty evidence. [Delavar MA (2025)]
  • 04Objectives The primary aim of this systematic review and meta-analysis of RCTs was to quantify the effects of inositol and its stereoisomers on anthropometric, and cardiometabolic measures. [Delavar MA (2025)]
The current Migaku evidence database contains 1 reusable source document for Inositol Cardiometabolic Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - Background Inositol and its derivatives may help mitigate risks associated with cardiovascular diseases; however, existing evidence remains inconsistent. [Delavar MA (2025); evidence level 1] - Heterogeneity was assessed via the Cochrane Chi-squared test and Galbraith plots, while the ROBI tool evaluated bias risk. [Delavar MA (2025); evidence level 1] - Significant reductions in BMI (WMD (95%CIs):-0.57 kg/m²(-1.10, -0.03), I²=88.6), waist-to-hip ratio(WMD (95%CI):-0.02(-0.04, -0.001), I²=84.1), and waist circumference (WMD (95%CI):-2.36 cm(-4.39, -0.33) I²=55.0) were noted with high heterogeneity and low to very low certainty evidence. [Delavar MA (2025); evidence level 1] - Objectives The primary aim of this systematic review and meta-analysis of RCTs was to quantify the effects of inositol and its stereoisomers on anthropometric, and cardiometabolic measures. [Delavar MA (2025); evidence level 1] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Learn next

Keep learning from this answer

GuideAshwagandha: What the Evidence Actually Says About Stress and CortisolLegacy library material — check the original sources.GuideMagnesium Glycinate benefits: what does the evidence sayLegacy library material — check the original sources.GuideProbiotics: What the Evidence Actually Supports (and What It Doesn't)Legacy library material — check the original sources.GuideL-Theanine: How It Works, What the Evidence Says, and How to Dose ItLegacy library material — check the original sources.DataMyo-Inositol Cardiometabolic Markers Randomized Trial Evidence TableLegacy library material — check the original sources.DataInositol Polycystic Ovary Syndrome Meta-Analysis Evidence TableLegacy library material — check the original sources.DataInositol Metabolic Markers Randomized Trial Evidence TableLegacy library material — check the original sources.

Sources

  1. Inositol supplementation efficacy in improving key cardiometabolic and anthropometric indices: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials.